Improving Diagnosis and Treatment of Atopic Dermatitis through Collaborative Primary & Specialist Care

Release date: March 12, 2019
Expiration date: March 12, 2020
Estimated time to complete activity: 1.0 hour(s)



Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor
Dermatology, Preventive Medicine and Medical Social Services
Director, Multidisciplinary Eczema Center and Patch Testing Clinic
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Stephen Brunton, MD
Adjunct Associate Professor
Department of Family Medicine
Touro University
Vallejo, California


Patients with atopic dermatitis (AD) are sub-optimally managed in current clinical practice and hence report a poor quality of life and high burden from their disease and comorbidities. There is a need to improve the diagnosis, assessment of severity, treatment, and management of AD to enable improved outcomes and quality of life among patients. This program will improve healthcare professionals’ ability to accurately diagnose and recognize AD among patients presenting with eczema by informing participants about updated diagnostic criteria and assessment scores to differentially diagnose AD and its severity. Discussions on updated guidelines, recommendations, and recent clinical evidence will be also included and evaluated to inform treatment decisions that alleviate the symptom burden of AD. Finally, clinicians will learn strategies to improve communication and adherence to treatment, and address the comorbidities of AD.


This educational initiative has been designed for primary care and family physicians, nurse practitioners, and physician assistants involved in the management of patients with AD.


Upon completion of this educational activity, participants will be able to:

  • Utilize updated criteria and guidelines to accurately diagnose AD and assess severity in individual patients
  • Review updated guidelines and evaluate available clinical data for therapies utilized in the treatment of AD
  • Describe indications for specialist referral of patients with AD and review best practices for co-management of moderate-to-severe disease with specialist physicians
  • List documentation and prior authorization requirements to ensure access to prescribed medications for patients with AD

There are no fees for participating and receiving CME credit for this activity. During the period of March 12, 2019 through March 12, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Jonathan I. Silverberg, MD, PhD, MPH
Consulting Fees:  AbbVie Inc.; Asana BioSciences, LLC; Dermavant Sciences, Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; GlaxoSmithKline Plc; Glenmark Pharmaceuticals; Incyte Corporation; Kiniksa Pharmaceuticals, Ltd.; Leo Pharma Inc.; Menlo Therapeutics; Pfizer Inc.; Realm Therapeutics, Inc.; Sanofi Genzyme/Regeneron Pharmaceuticals
Fees for Non-CME Services:  Sanofi Genzyme/Regeneron Pharmaceuticals
Contracted Research:  GlaxoSmithKline Plc 

Stephen Brunton, MD
Has no real or apparent conflict of interest to disclose.

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Continue to Pretest